Literature DB >> 17483325

Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells.

Maximilian Reichert1, Dieter Saur, Rainer Hamacher, Roland M Schmid, Günter Schneider.   

Abstract

The phosphoinositide-3-kinase (PI3K)/AKT signaling pathway controls fundamental processes of cancer cell biology like proliferation and cell survival. The PI3K/AKT pathway is activated in pancreatic ductal adenocarcinoma (PDAC) cells. The molecular mechanisms linking PI3K signaling to the cell cycle machinery in PDAC cells are not investigated in detail. Using the PI3K inhibitor Ly294002 as well as small interfering RNA targeting AKT1 expression, we show that PI3K controls the proliferation and G(1) phase progression of PDAC cells. Gene profiling revealed several important regulators of G(1)-S phase progression controlled by PI3K signaling like p21(Cip1), S-phase kinase-associated protein 2 (SKP2), CDC25a, cyclin A, cyclin D2, CDK2, and cyclin E. We show that the F-box protein SKP2, an oncogene up-regulated in PDAC, is transcriptionally regulated by the PI3K/AKT1 pathway in PDAC cells. At the molecular level, the control of the SKP2 gene by PI3K is due to the regulation of E2F1 binding to the proximal SKP2 gene promoter. The complex and profound connection of PI3K/AKT1 signaling to the cell cycle qualifies this pathway as a suitable target for therapeutic intervention in PDAC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483325     DOI: 10.1158/0008-5472.CAN-06-4484

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  45 in total

1.  Molecular imaging of Cathepsin E-positive tumors in mice using a novel protease-activatable fluorescent probe.

Authors:  Wael R Abd-Elgaliel; Zobeida Cruz-Monserrate; Craig D Logsdon; Ching-Hsuan Tung
Journal:  Mol Biosyst       Date:  2011-09-20

Review 2.  Pancreatic ductal adenocarcinoma and transcription factors: role of c-Myc.

Authors:  Anouchka Skoudy; Inmaculada Hernández-Muñoz; Pilar Navarro
Journal:  J Gastrointest Cancer       Date:  2011-06

Review 3.  Dysregulation of ubiquitin ligases in cancer.

Authors:  Jianfei Qi; Ze'ev A Ronai
Journal:  Drug Resist Updat       Date:  2015-09-28       Impact factor: 18.500

4.  Foxo3a transcription factor is a negative regulator of Skp2 and Skp2 SCF complex.

Authors:  J Wu; S-W Lee; X Zhang; F Han; S-Y Kwan; X Yuan; W-L Yang; Y S Jeong; A H Rezaeian; Y Gao; Y-X Zeng; H-K Lin
Journal:  Oncogene       Date:  2012-02-06       Impact factor: 9.867

5.  Rapamycin resistance is linked to defective regulation of Skp2.

Authors:  Hana Totary-Jain; Despina Sanoudou; Cula N Dautriche; Hillary Schneller; Lester Zambrana; Andrew R Marks
Journal:  Cancer Res       Date:  2012-02-06       Impact factor: 12.701

6.  JAZ mediates G1 cell cycle arrest by interacting with and inhibiting E2F1.

Authors:  Mingli Yang; Song Wu; Jinghua Jia; W Stratford May
Journal:  Cell Cycle       Date:  2011-07-15       Impact factor: 4.534

Review 7.  Pancreatic carcinogenesis.

Authors:  Jan-Bart M Koorstra; Steven R Hustinx; G Johan A Offerhaus; Anirban Maitra
Journal:  Pancreatology       Date:  2008-04-01       Impact factor: 3.996

8.  HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

Authors:  Susanne Schüler; Petra Fritsche; Sandra Diersch; Alexander Arlt; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  Mol Cancer       Date:  2010-04-16       Impact factor: 27.401

9.  IkappaBbeta is an essential co-activator for LPS-induced IL-1beta transcription in vivo.

Authors:  Melanie Scheibel; Bettina Klein; Heidrun Merkle; Manon Schulz; Ralph Fritsch; Florian R Greten; Melek C Arkan; Günter Schneider; Roland M Schmid
Journal:  J Exp Med       Date:  2010-10-25       Impact factor: 14.307

10.  Akt finds its new path to regulate cell cycle through modulating Skp2 activity and its destruction by APC/Cdh1.

Authors:  Daming Gao; Hiroyuki Inuzuka; Alan Tseng; Wenyi Wei
Journal:  Cell Div       Date:  2009-06-23       Impact factor: 5.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.